2026 — OPRM1 promoter hypermethylation in ME/CFS / FM
One-paragraph summary
Repeated-measures study of epigenetic dysregulation in 28 ME/CFS/FM patients vs. 26 matched healthy controls across two visits within four days. Methodology: blood sampling for epigenetic analysis; targeted pyrosequencing of OPRM1, COMT, and BDNF promoter regions; global DNA (hydroxy)methylation by LC-MS/MS; clinical questionnaire battery and quantitative sensory testing. Result: patients show significantly higher OPRM1 promoter methylation (the μ-opioid receptor gene), which remained significant after adjusting for symptom severity and QST findings. No significant global (hydroxy)methylation differences. Patients reported significantly worse symptom outcomes. For the project, this is the first directly-FM-relevant epigenetic finding in the project's evidence base — Hypothesis 2 framing predicts that heritable substrate would be measurable at the epigenetic level; OPRM1 hypermethylation gives a specific gene + mechanism for FM/ME-CFS that is independent of the broader epigenetic-clock framework.
Claims as triples
OPRM1_hypermethylation — present_in → fm_central_only[evidence: targeted pyrosequencing in n=28 ME/CFS/FM patients vs n=26 controls; confidence: emerging]OPRM1_hypermethylation — modulates → widespread_pain[evidence: μ-opioid receptor signaling reduction; confidence: bridging]epigenetic_dysregulation — bridges → fm_central_only[evidence: first FM-direct epigenetic finding in project; confidence: emerging]
Triangulation notes
- First epigenetic-mechanism FM paper in the project's evidence base. Closes a gap in Hypothesis 2's substrate framing — Kerrebijn 2025 provides the GWAS anchor; this paper provides the epigenetic-mechanism anchor.
- Connects to the project's existing low-dose-naltrexone (LDN) cure-path consideration — LDN modulates the endogenous opioid system; OPRM1 hypermethylation provides a candidate mechanism for why LDN works in some FM patients but not others.
- Discovered via Probe 1 (epigenetic clock / biological age); scored ingestion-worthy; promoted in Recommendation 3.
Open questions raised
- Does OPRM1 hypermethylation stratify FM patients by LDN responsiveness?
- Is OPRM1 hypermethylation reversible (e.g., by HDAC inhibitors like valproate per the 2026 maternal-separation paper)?